Testing inebilizumab for autoimmune hepatitis not helped by standard care
Treatments studied
Part of Digestive system, Immune system & allergy clinical trials.
This study tests a new biologic medicine called inebilizumab that may help people whose autoimmune hepatitis hasn't improved with standard treatments. The goal is to see if it can reduce liver inflammation and improve their condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a liver biopsy (taken within 90 days before the trial starts) that clearly shows autoimmune hepatitis.
- Your liver enzyme (ALT) levels are moderately high—about 2 to 7 times above the normal range.
- You have tried standard treatments (like prednisone, azathioprine, or mycophenolate) for at least 9 months and they haven't worked well, or you can't take them due to side effects.
- You are on a stable dose of your current liver medication for at least 12 weeks before the trial.
- You agree to use effective birth control during the treatment and for 6 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called belimumab for people with autoimmune hepatitis that is not well controlled. It aims to see if adding belimumab to your current treatment can help reduce liver inflammation.
This study compares two medicines, azathioprine and mycophenolate mofetil, to see which works better for treating autoimmune hepatitis. If you haven't been treated before, this trial could help find a more effective way to manage your condition.
This study looks at what factors affect how well the liver responds to treatment in people with autoimmune hepatitis. It may help doctors understand why some people respond better than others and could lead to more personalized care.
This study follows people with autoimmune hepatitis (a condition where the immune system attacks the liver) and requires key blood test results at diagnosis. It may help doctors better understand this disease and how it progresses in patients in China.
This trial tests a drug called Siplizumab in people with autoimmune hepatitis or primary sclerosing cholangitis who are on the liver transplant waitlist. It aims to see if the drug can help manage their condition before and after transplant.
This trial tests a new treatment called inebilizumab for type 1 autoimmune pancreatitis, a condition where the immune system attacks the pancreas. The goal is to see if this treatment can reduce symptoms and prevent damage to the pancreas and other organs.
Hear when a new Autoimmune Hepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.